Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics has demonstrated strong potential for its FSdC program, showcasing statistically robust and sustained improvements compared to comparator fibroblast approaches, positioning it as a differentiated solution for chronic spinal conditions. The company's preclinical results indicate meaningful structural restoration of intervertebral disc integrity, suggesting that FSdC may not only provide symptomatic relief but also act as a disease-modifying therapy for degenerative disc disease. Furthermore, the promising advancements in the pipeline, particularly with CYPS317, reveal the potential for significant therapeutic effects and broaden FibroBiologics' market reach into large musculoskeletal applications, thereby reinforcing a favorable outlook for the company's stock.

Bears say

The financial outlook for FibroBiologics Inc is challenged by significant risks, including the potential failure of its developmental candidates to meet projected commercial revenue estimates, which could stem from limitations in market size, penetration rates, and pricing strategies. Additionally, the company faces uncertainties regarding its ability to secure adequate capital resources for ongoing operations, which could hamper its development efforts. Lastly, ongoing program development and commercialization activities carry inherent risks, particularly related to the timing of warrant exercises and the conversion of proceeds, which may affect liquidity and the company’s overall capital runway.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.